Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 15, 2021 - Issue
Submit an article Journal homepage
270
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Development of UPLC-MS/MS Method for Studying the Pharmacokinetic Interaction Between Dasatinib and Posaconazole in Rats

Suili Yang1 Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
,
Xiaoshan Zhang2 College of Pharmacy, Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China;3 Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
,
Yuzhen Wang2 College of Pharmacy, Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China;3 Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
,
Congcong Wen4 Laboratory Animal Center, Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
,
Chenxiang Wang3 Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
,
Ziye Zhou5 Clinical Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-0294-7399
ORCID Icon &
Guanyang Lin3 Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of ChinaCorrespondence[email protected] [email protected]
 show all
Pages 2171-2178 | Published online: 24 May 2021

References

  • TalpazM, ShahNP, KantarjianH, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New Engl J Med. 2006;354(24):2531–2541. doi:10.1056/NEJMoa05522916775234
  • ShahNP, TranC, LeeFY, ChenP, NorrisD, SawyersCL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399–401. doi:10.1126/science.109948015256671
  • KeatingGM. Dasatinib: a Review in Chronic Myeloid Leukaemia and Ph plus Acute Lymphoblastic Leukaemia. Drugs. 2017;77(1):85–96. doi:10.1007/s40265-016-0677-x28032244
  • KorashyHM, RahmanAFMM, KassemMG. Dasatinib. Profiles Drug Subst Excip Relat Methodol. 2014;205–237. doi:10.1016/B978-0-12-800173-8.00004-024794907
  • LennmyrE, KarlssonK, AhlbergL, et al. Survival in adult acute lymphoblastic leukaemia (ALL): a report from the Swedish ALL Registry. Eur J Haematol. 2019;103(2):88–98. doi:10.1111/ejh.1324731074910
  • SlaytonWB, SchultzKR, KairallaJA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children’s Oncology Group Trial AALL0622. J Clin Oncol. 2018;36(22):2306–2314. doi:10.1200/JCO.2017.76.7228
  • MarietteC, TavernierE, HocquetD, et al. Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. Leukemia Lymphoma. 2017;58(3):586–593. doi:10.1080/10428194.2016.120465227397551
  • KengMHB, KengHLC, TanBH, WongGC. High risk of invasive fungal infections in adult acute lymphoblastic leukemia patients receiving induction and salvage chemotherapy. Leukemia Lymphoma. 2017;58(8):2017–2018. doi:10.1080/10428194.2016.126735127931145
  • CornelyOA, RobertsonMN, HaiderS, et al. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemoth. 2017;72(12):3501–3413. doi:10.1093/jac/dkx382
  • GirmeniaC, BuscaA, CandoniA, et al. Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: an Italian consensus agreement on definitions and management. Med Mycol. 2019;57:S127–S137. doi:10.1093/mmy/myy09130816979
  • WongTY, LooYS, VeettilSK, et al. Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis. Sci Rep-Uk. 2020;10(1):14575. doi:10.1038/s41598-020-71571-0
  • WangLF, ChristopherLJ, CuiDH, et al. Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008;36(9):1828–1839. doi:10.1124/dmd.107.02025518556438
  • LiXH, HeYJ, RuizCH, KoenigM, CameronMD. Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab Dispos. 2009;37(6):1242–1250. doi:10.1124/dmd.108.02593219282395
  • JohnsonFM, AgrawalS, BurrisH, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer-Am Cancer Soc. 2010;116(6):1582–1591. doi:10.1002/cncr.24927
  • LinJH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliver Rev. 2003;55(1):53–81. doi:10.1016/S0169-409X(02)00171-0
  • ChaeH, ChoSY, YuH, et al. Determination of posaconazole concentration with LC-MS/MS in adult patients with hematologic malignancy. Clin Chim Acta. 2015;450:220–226. doi:10.1016/j.cca.2015.08.02326319883
  • AlzomanNZ, MaherHM, ShehataSM, AbanmyNO. UPLC-MS/MS study of the effect of dandelion root extract on the plasma levels of the selected irreversible tyrosine kinase inhibitors dasatinib, imatinib and nilotinib in rats: potential risk of pharmacokinetic interactions. Biomed Chromatogr. 2019;33(12):e4674. doi:10.1002/bmc.467431376170
  • MaherHM, AlzomanNZ, ShehataSM, AbanmyNO. Validated UPLC-MS/MS method for the quantification of dasatinib in plasma: application to pharmacokinetic interaction studies with nutraceuticals in Wistar rats. PLoS One. 2018;13(6):e0199208. doi:10.1371/journal.pone.019920829902246
  • ZengJ, CaiHL, JiangZP, et al. A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. J Pharm Anal. 2017;7(6):374–380. doi:10.1016/j.jpha.2017.07.00929404062
  • BasuSS, PetridesA, MasonDS, JarolimP. A rapid UPLC-MS/MS assay for the simultaneous measurement of fluconazole, voriconazole, posaconazole, itraconazole, and hydroxyitraconazole concentrations in serum. Clin Chem Lab Med. 2017;55(6):836–844. doi:10.1515/cclm-2016-041827866173

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.